Actively Recruiting
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Led by Tongji Hospital · Updated on 2025-12-18
144
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is for patients with early-stage liver cancer who are planning to have surgery. The goal of this research is to see if a personalized treatment plan, guided by a computer model (an artificial intelligence tool), can help prevent the cancer from coming back after surgery. First, the computer model will analyze each patient's medical images and health data to predict their personal risk of the cancer returning. Patients whom the model predicts have a high risk of the cancer coming back will be offered a special treatment plan. This plan involves receiving medication (neoadjuvant therapy) before surgery and additional medication (adjuvant therapy) after surgery. The effectiveness of this plan will be compared to the standard approach of surgery alone. The main goal is to see if this new, personalized plan can better prevent the cancer from returning within 2 years after surgery. The study will also closely monitor the safety of the medications used. All patients in the study will be followed closely for 2 years with regular scans and check-ups to monitor their health.
CONDITIONS
Official Title
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 75 years who can understand and voluntarily sign informed consent
- Clinical diagnosis of BCLC stage 0-A hepatocellular carcinoma confirmed by histopathology or imaging
- Scheduled for curative-intent liver resection surgery
- Predicted high risk of aggressive cancer recurrence by the pre-operative deep learning model (PRE score 2 0.5)
- Child-Pugh liver function class A (score 2 7)
- ECOG Performance Status of 0 or 1
- Availability of a standard pre-operative MRI scan within 1 month before enrollment with acceptable quality
- Willing and able to comply with study procedures and follow-up for at least 2 years
You will not qualify if you...
- Postoperative pathology confirming non-hepatocellular carcinoma malignancy
- History of other active cancers in the past 5 years except certain low-risk treated cancers
- Death or loss to follow-up within 90 days after surgery
- Known allergy to any part of the neoadjuvant therapy drugs (oxaliplatin, fluorouracil, PD-1 inhibitors, lenvatinib)
- Severe uncontrolled medical conditions such as NYHA Class III/IV heart failure, severe kidney problems, or uncontrolled high blood pressure
- Any condition that would prevent participation or affect study evaluation, as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital
Wuhan, Hubei, China, 438700
Actively Recruiting
Research Team
Y
Yang Wu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here